# OnCo record phallcon (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/phallcon/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "phallcon", "NCT03589326" ;
  schema:name "PhALLCON"@en ;
  schema:description "Head to head, the third-generation TKI ponatinib doubled the rate of deep, undetectable remission over imatinib in newly diagnosed Ph-positive ALL."@en ;
  schema:url <https://onco.cc/trials/phallcon/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03589326> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-10-04" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:drugs <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/imatinib/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:terms <https://onco.cc/terms/ph-positive-all/>, <https://onco.cc/terms/mrd-negative-cr/> .